



## **The Role of Immunotherapy in Stage III NSCLC**

### **The PACIFIC Trail and Imfinzi**

**Presented by Karen Kelly, MD**

**Associate Director for Clinical Research**

**UC Davis Comprehensive Cancer Center**

### **TRANSCRIPT**

Hi, I'm Karen Kelly professor of medicine at the University of California Davis in Sacramento California. I'd like to share with you today a new standard of care for patients who have stage III inoperable lung cancer. Patients who have stage III lung cancer have up till now been treated with chemotherapy concurrently with radiation therapy. Today, based upon a trial called PACIFIC, patients now receive additional therapy with a drug called Imfinzi. Let me go over that trial with you.

PACIFIC randomized patients after they completed chemo radiation therapy and had not progressed and patients who did not have any autoimmune disease were asked to enroll into this trial and be randomized to getting Imfinzi which was given IV every two weeks for a year versus placebo. Now, in this trial we showed that patients had a longer time to progression if they got Imfinzi versus placebo. More recently, we were told that the now overall survival benefit also favors the patients who got treated with Imfinzi. Based upon the progression-free result, Imfinzi is now FDA approved for patients who have completed their chemo radiation and then can be given Imfinzi for a year. Importantly, this agent is very well tolerated.

<https://www.youtube.com/watch?v=80FGjRFXj7Y&feature=youtu.be>